The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pulmonary Drugs-Global Market Insights and Sales Trends 2025
Synopsis
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
The global Pulmonary Drugs market size is expected to reach US$ 70880 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Drugs in various end use industries. The expanding demands from the Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension and Cystic Fibrosis, are propelling Pulmonary Drugs market. Inhaled Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Long Acting Beta-2 Agonists segment is estimated at % CAGR for the next seven-year period.
Increasing tobacco smoking is expected to augment global pulmonary drugs market growth over forecast period.
Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2021, tobacco smoking is the primary cause of COPD leading to around 90% of Chronic Obstructive Pulmonary Disease (COPD) cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma. For instance, in March 2022, according Centers for Disease Control (CDC), 30.8 billion adults in the U.S. smoked. Nearly 40 billion U.S. adults still smoke cigarettes, and an estimated 2.55 billion middle and high school students use at least one tobacco product, including e-cigarettes according statistical data provided in March 2022. For instance, September 2020, according to artoicle published in National Center for Biotechnology Information, every day, about 1,600 U.S. youth younger than 18 years smoke their first cigarette. Each year, nearly half a billion U.S. citizens die prematurely of smoking or exposure to secondhand smoke. Another 16 billion live with a serious illness caused by smoking. Each year, the U.S. spends more than $225 billion on medical care to treat smoking-related disease in adults.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pulmonary Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pulmonary Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pulmonary Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pulmonary Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pulmonary Drugs covered in this report include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceutici S.p.A, Zambon Company S.p.A and Alaxia SAS, etc.
The global Pulmonary Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
Boehringer Ingelheim
Grifols, S.A.
Abbott Laboratories
AbbVie Inc.
Aerogen Pharma Ltd.
Aurobindo Pharma Ltd.
Celon Pharma SA
Cipla Ltd.
F. Hoffmann La Roche Ltd.
Glenmark Pharmaceuticals Ltd.
Lupin Ltd.
Medisol Lifescience Pvt. Ltd.
Novartis AG
Sumitomo Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.
Wellona Pharma
Global Pulmonary Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pulmonary Drugs market, Segment by Type:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Global Pulmonary Drugs market, by Application
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pulmonary Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
The global Pulmonary Drugs market size is expected to reach US$ 70880 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Drugs in various end use industries. The expanding demands from the Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension and Cystic Fibrosis, are propelling Pulmonary Drugs market. Inhaled Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Long Acting Beta-2 Agonists segment is estimated at % CAGR for the next seven-year period.
Increasing tobacco smoking is expected to augment global pulmonary drugs market growth over forecast period.
Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2021, tobacco smoking is the primary cause of COPD leading to around 90% of Chronic Obstructive Pulmonary Disease (COPD) cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma. For instance, in March 2022, according Centers for Disease Control (CDC), 30.8 billion adults in the U.S. smoked. Nearly 40 billion U.S. adults still smoke cigarettes, and an estimated 2.55 billion middle and high school students use at least one tobacco product, including e-cigarettes according statistical data provided in March 2022. For instance, September 2020, according to artoicle published in National Center for Biotechnology Information, every day, about 1,600 U.S. youth younger than 18 years smoke their first cigarette. Each year, nearly half a billion U.S. citizens die prematurely of smoking or exposure to secondhand smoke. Another 16 billion live with a serious illness caused by smoking. Each year, the U.S. spends more than $225 billion on medical care to treat smoking-related disease in adults.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pulmonary Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pulmonary Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pulmonary Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pulmonary Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pulmonary Drugs covered in this report include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceutici S.p.A, Zambon Company S.p.A and Alaxia SAS, etc.
The global Pulmonary Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
Boehringer Ingelheim
Grifols, S.A.
Abbott Laboratories
AbbVie Inc.
Aerogen Pharma Ltd.
Aurobindo Pharma Ltd.
Celon Pharma SA
Cipla Ltd.
F. Hoffmann La Roche Ltd.
Glenmark Pharmaceuticals Ltd.
Lupin Ltd.
Medisol Lifescience Pvt. Ltd.
Novartis AG
Sumitomo Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.
Wellona Pharma
Global Pulmonary Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pulmonary Drugs market, Segment by Type:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Global Pulmonary Drugs market, by Application
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pulmonary Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Pulmonary Drugs
1.1 Pulmonary Drugs Market Overview
1.1.1 Pulmonary Drugs Product Scope
1.1.2 Pulmonary Drugs Market Status and Outlook
1.2 Global Pulmonary Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pulmonary Drugs Market Size by Region (2018-2029)
1.4 Global Pulmonary Drugs Historic Market Size by Region (2018-2023)
1.5 Global Pulmonary Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pulmonary Drugs Market Size (2018-2029)
1.6.1 North America Pulmonary Drugs Market Size (2018-2029)
1.6.2 Europe Pulmonary Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Pulmonary Drugs Market Size (2018-2029)
1.6.4 Latin America Pulmonary Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Pulmonary Drugs Market Size (2018-2029)
2 Pulmonary Drugs Market by Type
2.1 Introduction
2.1.1 Inhaled Corticosteroids
2.1.2 Long Acting Beta-2 Agonists
2.1.3 Antihistamines
2.1.4 Vasodilators
2.1.5 Others
2.2 Global Pulmonary Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pulmonary Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Pulmonary Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pulmonary Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pulmonary Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pulmonary Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pulmonary Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pulmonary Drugs Revenue Breakdown by Type (2018-2029)
3 Pulmonary Drugs Market Overview by Application
3.1 Introduction
3.1.1 Asthma & COPD
3.1.2 Allergic Rhinitis
3.1.3 Pulmonary Arterial Hypertension
3.1.4 Cystic Fibrosis
3.1.5 Others
3.2 Global Pulmonary Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pulmonary Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Pulmonary Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pulmonary Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pulmonary Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pulmonary Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pulmonary Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pulmonary Drugs Revenue Breakdown by Application (2018-2029)
4 Pulmonary Drugs Competition Analysis by Players
4.1 Global Pulmonary Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Drugs as of 2022)
4.3 Date of Key Players Enter into Pulmonary Drugs Market
4.4 Global Top Players Pulmonary Drugs Headquarters and Area Served
4.5 Key Players Pulmonary Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Pulmonary Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Sanofi SA
5.1.1 Sanofi SA Profile
5.1.2 Sanofi SA Main Business
5.1.3 Sanofi SA Pulmonary Drugs Products, Services and Solutions
5.1.4 Sanofi SA Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Sanofi SA Recent Developments
5.2 Meda Pharmaceuticals
5.2.1 Meda Pharmaceuticals Profile
5.2.2 Meda Pharmaceuticals Main Business
5.2.3 Meda Pharmaceuticals Pulmonary Drugs Products, Services and Solutions
5.2.4 Meda Pharmaceuticals Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Meda Pharmaceuticals Recent Developments
5.3 Circassia Pharmaceuticals Plc.
5.3.1 Circassia Pharmaceuticals Plc. Profile
5.3.2 Circassia Pharmaceuticals Plc. Main Business
5.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Products, Services and Solutions
5.3.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 AstraZeneca Plc. Recent Developments
5.4 AstraZeneca Plc.
5.4.1 AstraZeneca Plc. Profile
5.4.2 AstraZeneca Plc. Main Business
5.4.3 AstraZeneca Plc. Pulmonary Drugs Products, Services and Solutions
5.4.4 AstraZeneca Plc. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 AstraZeneca Plc. Recent Developments
5.5 GlaxoSmithKline Plc.
5.5.1 GlaxoSmithKline Plc. Profile
5.5.2 GlaxoSmithKline Plc. Main Business
5.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Products, Services and Solutions
5.5.4 GlaxoSmithKline Plc. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 GlaxoSmithKline Plc. Recent Developments
5.6 Mallinckrodt Pharmaceuticals Plc.
5.6.1 Mallinckrodt Pharmaceuticals Plc. Profile
5.6.2 Mallinckrodt Pharmaceuticals Plc. Main Business
5.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Products, Services and Solutions
5.6.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments
5.7 Cheisi Farmaceutici S.p.A
5.7.1 Cheisi Farmaceutici S.p.A Profile
5.7.2 Cheisi Farmaceutici S.p.A Main Business
5.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Products, Services and Solutions
5.7.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Cheisi Farmaceutici S.p.A Recent Developments
5.8 Zambon Company S.p.A
5.8.1 Zambon Company S.p.A Profile
5.8.2 Zambon Company S.p.A Main Business
5.8.3 Zambon Company S.p.A Pulmonary Drugs Products, Services and Solutions
5.8.4 Zambon Company S.p.A Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Zambon Company S.p.A Recent Developments
5.9 Alaxia SAS
5.9.1 Alaxia SAS Profile
5.9.2 Alaxia SAS Main Business
5.9.3 Alaxia SAS Pulmonary Drugs Products, Services and Solutions
5.9.4 Alaxia SAS Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Alaxia SAS Recent Developments
5.10 Merck Sharp & Dohme Limited
5.10.1 Merck Sharp & Dohme Limited Profile
5.10.2 Merck Sharp & Dohme Limited Main Business
5.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Products, Services and Solutions
5.10.4 Merck Sharp & Dohme Limited Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Merck Sharp & Dohme Limited Recent Developments
5.11 Boehringer Ingelheim
5.11.1 Boehringer Ingelheim Profile
5.11.2 Boehringer Ingelheim Main Business
5.11.3 Boehringer Ingelheim Pulmonary Drugs Products, Services and Solutions
5.11.4 Boehringer Ingelheim Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Boehringer Ingelheim Recent Developments
5.12 Grifols, S.A.
5.12.1 Grifols, S.A. Profile
5.12.2 Grifols, S.A. Main Business
5.12.3 Grifols, S.A. Pulmonary Drugs Products, Services and Solutions
5.12.4 Grifols, S.A. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Grifols, S.A. Recent Developments
5.13 Abbott Laboratories
5.13.1 Abbott Laboratories Profile
5.13.2 Abbott Laboratories Main Business
5.13.3 Abbott Laboratories Pulmonary Drugs Products, Services and Solutions
5.13.4 Abbott Laboratories Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Abbott Laboratories Recent Developments
5.14 AbbVie Inc.
5.14.1 AbbVie Inc. Profile
5.14.2 AbbVie Inc. Main Business
5.14.3 AbbVie Inc. Pulmonary Drugs Products, Services and Solutions
5.14.4 AbbVie Inc. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 AbbVie Inc. Recent Developments
5.15 Aerogen Pharma Ltd.
5.15.1 Aerogen Pharma Ltd. Profile
5.15.2 Aerogen Pharma Ltd. Main Business
5.15.3 Aerogen Pharma Ltd. Pulmonary Drugs Products, Services and Solutions
5.15.4 Aerogen Pharma Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Aerogen Pharma Ltd. Recent Developments
5.16 Aurobindo Pharma Ltd.
5.16.1 Aurobindo Pharma Ltd. Profile
5.16.2 Aurobindo Pharma Ltd. Main Business
5.16.3 Aurobindo Pharma Ltd. Pulmonary Drugs Products, Services and Solutions
5.16.4 Aurobindo Pharma Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.16.5 Aurobindo Pharma Ltd. Recent Developments
5.17 Celon Pharma SA
5.17.1 Celon Pharma SA Profile
5.17.2 Celon Pharma SA Main Business
5.17.3 Celon Pharma SA Pulmonary Drugs Products, Services and Solutions
5.17.4 Celon Pharma SA Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.17.5 Celon Pharma SA Recent Developments
5.18 Cipla Ltd.
5.18.1 Cipla Ltd. Profile
5.18.2 Cipla Ltd. Main Business
5.18.3 Cipla Ltd. Pulmonary Drugs Products, Services and Solutions
5.18.4 Cipla Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.18.5 Cipla Ltd. Recent Developments
5.19 F. Hoffmann La Roche Ltd.
5.19.1 F. Hoffmann La Roche Ltd. Profile
5.19.2 F. Hoffmann La Roche Ltd. Main Business
5.19.3 F. Hoffmann La Roche Ltd. Pulmonary Drugs Products, Services and Solutions
5.19.4 F. Hoffmann La Roche Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.19.5 F. Hoffmann La Roche Ltd. Recent Developments
5.20 Glenmark Pharmaceuticals Ltd.
5.20.1 Glenmark Pharmaceuticals Ltd. Profile
5.20.2 Glenmark Pharmaceuticals Ltd. Main Business
5.20.3 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Products, Services and Solutions
5.20.4 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.20.5 Glenmark Pharmaceuticals Ltd. Recent Developments
5.21 Lupin Ltd.
5.21.1 Lupin Ltd. Profile
5.21.2 Lupin Ltd. Main Business
5.21.3 Lupin Ltd. Pulmonary Drugs Products, Services and Solutions
5.21.4 Lupin Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.21.5 Lupin Ltd. Recent Developments
5.22 Medisol Lifescience Pvt. Ltd.
5.22.1 Medisol Lifescience Pvt. Ltd. Profile
5.22.2 Medisol Lifescience Pvt. Ltd. Main Business
5.22.3 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Products, Services and Solutions
5.22.4 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.22.5 Medisol Lifescience Pvt. Ltd. Recent Developments
5.23 Novartis AG
5.23.1 Novartis AG Profile
5.23.2 Novartis AG Main Business
5.23.3 Novartis AG Pulmonary Drugs Products, Services and Solutions
5.23.4 Novartis AG Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.23.5 Novartis AG Recent Developments
5.24 Sumitomo Pharma Co. Ltd.
5.24.1 Sumitomo Pharma Co. Ltd. Profile
5.24.2 Sumitomo Pharma Co. Ltd. Main Business
5.24.3 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Products, Services and Solutions
5.24.4 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.24.5 Sumitomo Pharma Co. Ltd. Recent Developments
5.25 Teva Pharmaceutical Industries Ltd.
5.25.1 Teva Pharmaceutical Industries Ltd. Profile
5.25.2 Teva Pharmaceutical Industries Ltd. Main Business
5.25.3 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Products, Services and Solutions
5.25.4 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.25.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5.26 Vertex Pharmaceuticals Inc.
5.26.1 Vertex Pharmaceuticals Inc. Profile
5.26.2 Vertex Pharmaceuticals Inc. Main Business
5.26.3 Vertex Pharmaceuticals Inc. Pulmonary Drugs Products, Services and Solutions
5.26.4 Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.26.5 Vertex Pharmaceuticals Inc. Recent Developments
5.27 Wellona Pharma
5.27.1 Wellona Pharma Profile
5.27.2 Wellona Pharma Main Business
5.27.3 Wellona Pharma Pulmonary Drugs Products, Services and Solutions
5.27.4 Wellona Pharma Pulmonary Drugs Revenue (US$ Million) & (2018-2023)
5.27.5 Wellona Pharma Recent Developments
6 North America
6.1 North America Pulmonary Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Pulmonary Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pulmonary Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pulmonary Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pulmonary Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pulmonary Drugs Market Dynamics
11.1 Pulmonary Drugs Industry Trends
11.2 Pulmonary Drugs Market Drivers
11.3 Pulmonary Drugs Market Challenges
11.4 Pulmonary Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
